Bio-Techne
Other
Active
Minneapolis, United States
5
65M
5
0.12
3
- Areas of investment
Summary
In 1981 was created Bio-Techne, which is appeared as Corporate Investor. The main office of represented Corporate Investor is situated in the Minneapolis. The fund was located in North America if to be more exact in United States.
Among the various public portfolio startups of the fund, we may underline CyVek, ChemoCentryx Among the most popular fund investment industries, there are Health Diagnostics, Medical Device. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Moreover, a startup needs to be at the age of 6-10 years to get the investment from the fund.
The typical case for the fund is to invest in rounds with 2-3 participants. Despite the Bio-Techne, startups are often financed by OrbiMed, MPM Capital, Kaiser Permanente Ventures. The meaningful sponsors for the fund in investment in the same round are OrbiMed, Jennison Associates, HBM Healthcare Investments AG. In the next rounds fund is usually obtained by HBM Healthcare Investments AG, Glaxo Group, Alta Partners.
The fund was created by Roger C. Lucas Ph.D..
The fund is constantly included in less than 2 deals per year. The top activity for fund was in 2006. The increased amount of exits for fund were in 2014. The common things for fund are deals in the range of 10 - 50 millions dollars. Comparing to the other companies, this Bio-Techne performs on 71 percentage points more the average number of lead investments. The real fund results show that this Corporate Investor is 13 percentage points more often commits exit comparing to other companies.
Investor highlights
Discover reliable insights
Find relevant VC investors, identify key contacts and secure funding opportunities.
Investments analytics
Analytics
- Total investments
- 5
- Lead investments
- 0
- Exits
- 3
- Rounds per year
- 0.12
- Investments by industry
- Biotechnology (5)
- Health Care (2)
- Biopharma (1)
- Life Science (1)
- Medical Device (1) Show 8 more
- Investments by region
-
- United States (4)
- China (1)
- Peak activity year
- 2021
- Number of Unicorns
- 1
- Number of Decacorns
- 1
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 17
- Avg. valuation at time of investment
- 239M
- Group Appearance index
- 0.20
- Avg. company exit year
- 8
- Avg. multiplicator
- 0.78
- Strategy success index
- 0.50
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| ChemoCentryx | 24 Aug 2006 | Biotechnology, Health Care, Medical Device | Late Stage Venture | 17M | United States, California, Mountain View |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.